Literature DB >> 8738298

Somatostatin receptors in the rhesus monkey brain: localization and pharmacological characterization.

V S Thoss1, C Piwko, D Hoyer.   

Abstract

To characterize the nature and distribution of somatostatin (SRIF) receptors, radioligand binding studies and in vitro receptor autoradiography were performed in Rhesus monkey brain using either [125I]LTT-SRIF-28 ([Leu8, D-Trp22, 125I-Tyr25]SRIF-28) alone or in the presence of 3 nM seglitide (to block sst2 sites), [125I]Tyr3-octreotide or [125I]CGP 23996 (c[Asu-Lys-Asn-Phe-Trp-Lys-Thr-Tyr-Thr-Ser]) in buffer containing either 120 mM Na+ or 5 mM Mg2+. [125I]Tyr3 -octreotide labelled an apparently homogeneous population of sites in cerebral and cerebellar cortex (Bmax = 27.3 +/- 2.8 fmol/mg protein and 52.6 +/- 8.6 fmol/mg protein, PKd = 9.46 +/- 0.03 and] 9.93 +/- 0.03, respectively). The pharmacological profile of these sites correlated highly significantly with that of human recombinant sst2 receptors (r = 0.996), but not or much less with that of human recombinant sst3 and sst5 receptors (r = 0.12 and 0.45, respectively). [125I]CGP 23996 (in Na(+)-buffer) also labelled an apparently homogeneous population of sites in Rhesus monkey cerebral cortex membranes (Bmax = 3.1 +/- 0.3 fmol/mg protein, pKd = 10.57 +/- 0.08), the pharmacological profile of which was highly significantly correlated with the profiles of human recombinant sst1 and sst4 receptors (r = 0.98 and 0.96, respectively). Using receptor autoradiography, high levels of [125I]LTT-SRIF-28 and [125I]Tyr3 -octreotide recognition sites were found in basal ganglia, molecular and granular layers of the cerebellum and layers III, V and VI of entorhinal cortex. In these regions, the addition of 3 nM seglitide produced a marked decrease of [125I]LTT-SRIF-28 binding. Low levels of [125I]LTT-SRIF-28 binding were observed in subiculum, pituitary and choroid plexus. By contrast, [125I]CGP 23996 labelling in the presence of Mg2+ as well as Na+ ions was highest in pituitary and choroid plexus. However, [125I]CGP 23996 binding was diversely affected by these ionic conditions in several regions of hippocampus and cerebral cortex. Displacement of [125I]CGP 23996 (in Mg(2+)-buffer) with seglitide in the molecular layer of the cerebellum, deep layers of the entorhinal cortex, layers I, II and V of the insular cortex and frontal pole yielded complex competition curves suggesting the presence of two populations of SRIF receptors. By contrast, [125I]CGP 23996 binding (in Mg(2+)-buffer) in the choroid plexus, hilus of the dentate gyrus and stratum oriens and radiatum of the CA3 field of hippocampus was not affected by seglitide up to 10 microM, suggesting only sst1 and/or sst4 sites which have a negligible affinity for seglitide to be present in these structures. Taken together, these results suggest that [125I]CGP 23996 (in the presence of Na+) labels exclusively SRIF-2 receptors (sst1 and/or sst4), whereas in the presence of Mg2+ ions, [125I]CGP 23996 labels both SRIF-2 and SRIF-1 receptors (sst2, sst3 and sst5). The present study also demonstrates the presence and differential distribution of sst2 and sst1/sst4 receptors in the Rhesus monkey brain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738298     DOI: 10.1007/bf00167184

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  45 in total

1.  Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue.

Authors:  F Raulf; J Pérez; D Hoyer; C Bruns
Journal:  Digestion       Date:  1994       Impact factor: 3.216

2.  Regional distribution of high-affinity [3H]somatostatin binding sites in the human brain.

Authors:  C A Whitford; C A Bloxham; C R Snell; J M Candy; B H Hirst
Journal:  Brain Res       Date:  1986-11-19       Impact factor: 3.252

3.  Autoradiographic mapping of somatostatin receptors in the rat central nervous system and pituitary.

Authors:  J C Reubi; R Maurer
Journal:  Neuroscience       Date:  1985-08       Impact factor: 3.590

4.  Classification and nomenclature of somatostatin receptors.

Authors:  D Hoyer; G I Bell; M Berelowitz; J Epelbaum; W Feniuk; P P Humphrey; A M O'Carroll; Y C Patel; A Schonbrunn; J E Taylor
Journal:  Trends Pharmacol Sci       Date:  1995-03       Impact factor: 14.819

Review 5.  Distribution of somatostatin receptors in normal and tumor tissue.

Authors:  J C Reubi; L Kvols; E Krenning; S W Lamberts
Journal:  Metabolism       Date:  1990-09       Impact factor: 8.694

6.  Human cerebellar cortex possesses high affinity binding sites for [3H]somatostatin.

Authors:  C A Whitford; J M Candy; C A Bloxham; A E Oakley; C R Snell
Journal:  Eur J Pharmacol       Date:  1985-07-11       Impact factor: 4.432

7.  Characterization of cloned somatostatin receptors SSTR4 and SSTR5.

Authors:  K Raynor; A M O'Carroll; H Kong; K Yasuda; L C Mahan; G I Bell; T Reisine
Journal:  Mol Pharmacol       Date:  1993-08       Impact factor: 4.436

8.  Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides.

Authors:  K Raynor; W A Murphy; D H Coy; J E Taylor; J P Moreau; K Yasuda; G I Bell; T Reisine
Journal:  Mol Pharmacol       Date:  1993-06       Impact factor: 4.436

9.  Quantitative autoradiographic study of somatostatin receptors in the adult human cerebellum.

Authors:  A Laquerriere; P Leroux; C Bodenant; B Gonzalez; J Tayot; H Vaudry
Journal:  Neuroscience       Date:  1994-10       Impact factor: 3.590

10.  Different ionic requirements for somatostatin receptor subpopulations in the brain.

Authors:  J C Reubi; R Maurer
Journal:  Regul Pept       Date:  1986-07
View more
  2 in total

1.  Expression of five somatostatin receptor mRNAs in the human brain and pituitary.

Authors:  V S Thoss; J Pérez; A Probst; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

2.  A simple novel approach for detecting blood-brain barrier permeability using GPCR internalization.

Authors:  Z Csaba; T Vitalis; C Charriaut-Marlangue; I Margaill; B Coqueran; P-L Leger; I Parente; A Jacquens; L Titomanlio; C Constans; C Demene; M D Santin; S Lehericy; N Perrière; F Glacial; S Auvin; M Tanter; J-F Ghersi-Egea; H Adle-Biassette; J-F Aubry; P Gressens; P Dournaud
Journal:  Neuropathol Appl Neurobiol       Date:  2020-09-27       Impact factor: 8.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.